Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

In a $250 million buyback plan, Theravance Biopharma will acquire 9.6 million shares of its stock from GSK. (BioPharma Dive)

In a new clinical trial, Penn Medicine will test a chewing gum created by its School of Dental Medicine, designed to trap SARS-CoV-2 in the saliva, potentially blocking its transmission. (Penn Today)

Meanwhile, the World Health Organization's director, Tedros Adhanom Ghebreyesus, said that "the end is in sight" for the coronavirus pandemic.
(CBS News)

Nature examines the advances made in Artificial Intelligence, speeding the creation of novel molecules to aid in the fight against disease. According to its reporting, what once took scientists months now can be achieved in seconds.

The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!

‍

‍

‍

‍

Our Culture

“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.
Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”

      –Stephen, Lead Engineer

‍

‍‍

‍

‍

‍

About Judi

Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

‍